Abstract |
An association of 5-fluoruracyl (or methotrexate) and cyclophosphamide was used in the treatment of 20 cases of hormone-resistant breast cancer. Five objective regressions were obtained. Mean survival here was 28.25 (S.D. 2.87) months, as opposed to 12.75 (S.D. 6.93) months in the remainder. Side-effects of various kinds were noted in 9 patients.
|
Authors | R Germiniani, G Pipino, F Lavorato, S Bressani Doldi |
Journal | Minerva medica
(Minerva Med)
Vol. 68
Issue 13
Pg. 831-4
(Mar 17 1977)
ISSN: 0026-4806 [Print] Italy |
Vernacular Title | L'associazione di antimetaboliti ed alchilanti nel trattamento del cancro mammario in fase avanzata |
PMID | 321989
(Publication Type: Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Alkylating Agents
- Antimetabolites
- Cyclophosphamide
- Fluorouracil
|
Topics |
- Adult
- Aged
- Alkylating Agents
(therapeutic use)
- Antimetabolites
(therapeutic use)
- Breast Neoplasms
(drug therapy)
- Clinical Trials as Topic
- Cyclophosphamide
(administration & dosage, therapeutic use)
- Drug Therapy, Combination
- Female
- Fluorouracil
(administration & dosage, therapeutic use)
- Humans
- Middle Aged
- Time Factors
|